Zhang: META at "Good Entry Point," ELV Turnaround Intact, Bearish on CZR
@OptionsPlay's Tony Zhang says he's been "bullish for quite some time" on Meta Platforms (META) due to how it uses A.I. to boost advertising revenue.
Fiscal Year: January - December
Elevance Health, Inc. (ELV), listed on the NYSE, has a market capitalization of $. As of Oct 03, 2025, the stock is trading at $340.24 per share, offering investors a clear view of its current market value. Elevance Health, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 14.55, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Elevance Health, Inc. also offers a dividend yield of 2.01%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Elevance Health, Inc. (ELV) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Elevance Health, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Elevance Health, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Elevance Health, Inc. is 14.36, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Elevance Health, Inc. (ELV) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Elevance Health, Inc. (ELV) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Elevance Health, Inc. (ELV) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Elevance Health, Inc.. To access the full SS Score, consider upgrading your subscription.
Elevance Health, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 14.55. Investors should compare these metrics with industry peers to gauge whether Elevance Health, Inc. is outperforming or underperforming within its sector.
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review the...
Elevance Health is significantly undervalued, trading at a 41% discount to industry peers, despite strong revenue growth and a 2.11% dividend yield. ELV's recent selloff was triggered by bottom-line c...
INDIANAPOLIS--(BUSINESS WIRE)--Indianapolis Public Schools' Northwest Middle School today celebrated the unveiling of its newly transformed weight room, a project made possible through a partnership w...
OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has assigned a Long-Term Issue Credit Rating of “bbb+” (Good) to Elevance Health Inc.'s (Elevance Health) (headquartered in Indianapolis, IN) newly...
ELV stands out as an outperformer due to strong historical performance, capital returns, and a robust balance sheet. Sector tailwinds and AI-driven efficiency gains present attractive long-term opport...
INDIANAPOLIS--(BUSINESS WIRE)--The Elevance Health Foundation has awarded 29 new grants totaling more than $6.5 million to support maternal and infant health programs across the country. The funding w...
My Top 15 high-growth dividend stocks for September 2025 are collectively 32% undervalued and offer a 1.43% yield with 21.57% five-year dividend growth. The strategy's five-year annualized return is 1...
Elevance and peers face earnings pressure from rising medical costs, driven by deferred care, expensive drugs, and persistent medical inflation. The segment has re-rated, and now offers good value. In...
A federal judge in Texas on Tuesday rejected Elevance Health's challenge of the U.S. government's calculation for the health insurer's star ratings for some of its government-backed Medicare plans aft...
INDIANAPOLIS--(BUSINESS WIRE)-- #ElevanceHealth--Elevance Health and the National Association of Community Health Centers (NACHC) are proud to announce the integration of Food as Medicine (FAM) progra...
Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a li...
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...
INDIANAPOLIS--(BUSINESS WIRE)--The board of directors of Elevance Health (NYSE: ELV) announced today that Steve Collis, a highly regarded global healthcare executive, will be joining the company's boa...
On July 18, the CEO bought $2.4MM worth, after the sell-off following the last earnings call. Carelon Services is growing fast, supported by the December acquisition of CareBridge. The aging populatio...
INDIANAPOLIS--(BUSINESS WIRE)-- #DigitalHealth--Study by Elevance Health, UCI, in collaboration with Apple, highlights potential of digital health tools to reduce asthma burden in U.S. populations.
Major U.S. equities indexes pushed higher Thursday as a report revealed an increase in retail sales in June, suggesting that consumer spending remains strong despite tariff concerns.
Major U.S. equities indexes were higher at midday Thursday in the wake of better-than-expected quarterly results from several major companies. The Dow, S&P 500, and Nasdaq all advanced.
Elevance Health, Inc. (NYSE:ELV) Q2 2025 Earnings Conference Call July 17, 2025 8:30 AM ET Company Participants Felicia Farr Norwood - Executive VP & President of Government Health Benefits Gail Kozi...
The health insurer now expects 2025 earnings of just $30 a share, citing ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid.
A majority of publicly traded US health insurers are expected to post QoQ declines in revenue and net income in Q2, according to an S&P Global Market Intelligence analysis of sell-side analyst forecas...
Elevance lowered its annual profit forecast on Thursday as it expects elevated medical costs in its government-backed plans to persist, sending its shares 7% lower in premarket trading.
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that...
The market often misinterprets price declines as value. For Elevance Health, I see a disconnect between market cap and long-term earnings potential. Health sector valuations have dropped sharply, but ...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 6.39B | 40.29% | Est @40.3% |
2026 | 8.22B | 28.72% | Analyst x3 |
2027 | 8.08B | -1.73% | Analyst x2 |
2028 | 10.26B | 27.02% | Analyst x1 |
2029 | 11.31B | 10.23% | Analyst x1 |
2030 | 11.92B | 5.40% | Est @5.4% |
2031 | 12.45B | 4.47% | Est @4.5% |
2032 | 12.93B | 3.82% | Est @3.8% |
2033 | 13.37B | 3.37% | Est @3.4% |
2034 | 13.75B | 2.85% | Est @2.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 6.77B | 1.00 | 6.77B |
2024A | 4.55B | 1.00 | 4.55B |
2025E | 6.39B | 1.08 | 5.94B |
2026E | 8.22B | 1.16 | 7.10B |
2027E | 8.08B | 1.25 | 6.49B |
2028E | 10.26B | 1.34 | 7.66B |
2029E | 11.31B | 1.44 | 7.85B |
2030E | 11.92B | 1.55 | 7.69B |
2031E | 12.45B | 1.67 | 7.46B |
2032E | 12.93B | 1.79 | 7.20B |
2033E | 13.37B | 1.93 | 6.92B |
2034E | 13.75B | 2.08 | 6.62B |
Terminal | 277.04B | 2.08 | 133.35B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.